Symbols / AKBA
AKBA Chart
About
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 329.05M |
| Enterprise Value | 361.62M | Income | -15.90M | Sales | 225.07M |
| Book/sh | 0.16 | Cash/sh | 0.63 | Dividend Yield | — |
| Payout | 0.00% | Employees | 181 | IPO | — |
| P/E | — | Forward P/E | 24.80 | PEG | — |
| P/S | 1.46 | P/B | 7.90 | P/C | — |
| EV/EBITDA | 11.21 | EV/Sales | 1.61 | Quick Ratio | 1.74 |
| Current Ratio | 1.94 | Debt/Eq | 478.48 | LT Debt/Eq | — |
| EPS (ttm) | -0.08 | EPS next Y | 0.05 | EPS Growth | — |
| Revenue Growth | 57.00% | Earnings | 2026-02-26 | ROA | 4.80% |
| ROE | — | ROIC | — | Gross Margin | 83.32% |
| Oper. Margin | 7.57% | Profit Margin | -7.07% | Shs Outstand | 265.37M |
| Shs Float | 259.76M | Short Float | 14.06% | Short Ratio | 12.53 |
| Short Interest | — | 52W High | 4.08 | 52W Low | 1.14 |
| Beta | 0.37 | Avg Volume | 3.21M | Volume | 2.36M |
| Target Price | $4.60 | Recom | None | Prev Close | $1.21 |
| Price | $1.24 | Change | 2.48% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.60
Mean price target
2. Current target
$1.24
Latest analyst target
3. DCF / Fair value
$3.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.24
Low
$3.00
High
$6.00
Mean
$4.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-06 | main | Piper Sandler | Overweight → Overweight | $4 |
| 2026-02-06 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-12-02 | reit | BTIG | Buy → Buy | $5 |
| 2025-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-10-30 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-10-29 | main | BTIG | Buy → Buy | $5 |
| 2025-04-28 | init | Leerink Partners | — → Outperform | $7 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-04-01 | init | Jefferies | — → Buy | $6 |
| 2025-03-14 | main | Piper Sandler | Overweight → Overweight | $6 |
| 2025-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-01-23 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-10-23 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-10-08 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-03-28 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-03-15 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
- Piper Sandler Lowers Akebia Therapeutics (AKBA) PT to $4 as Firm Updates Estimates Following Year-End Reports - Yahoo Finance Fri, 20 Feb 2026 00
- New pill tested for rare kidney disease with no approved treatments - Stock Titan ue, 06 Jan 2026 08
- Akebia Therapeutics (AKBA) to Release Quarterly Earnings on Thursday - MarketBeat Fri, 20 Feb 2026 16
- Akebia Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire hu, 19 Feb 2026 13
- How Low Can Akebia Therapeutics Stock Really Go? - Trefis Sat, 20 Dec 2025 08
- New Analyst Forecast: $AKBA Given $5 Price Target | AKBA Stock News - Quiver Quantitative ue, 02 Dec 2025 08
- Akebia Therapeutics, Inc. (AKBA): Investor Outlook Reveals 289.83% Potential Upside - DirectorsTalk Interviews Sat, 21 Feb 2026 06
- Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook - simplywall.st ue, 07 Oct 2025 07
- Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance ue, 11 Nov 2025 08
- Akebia Therapeutics (NASDAQ:AKBA) CAO Sells $68,838.36 in Stock - MarketBeat Wed, 04 Feb 2026 08
- Drugmaker maps next steps in Vafseo use and rare kidney disease trials - Stock Titan Mon, 12 Jan 2026 08
- Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment? - simplywall.st Sun, 10 Aug 2025 07
- New Analyst Forecast: $AKBA Given $5.0 Price Target - Quiver Quantitative Wed, 29 Oct 2025 07
- H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy - Yahoo Finance Fri, 25 Jul 2025 07
- Q32 Bio (NASDAQ: QTTB) gets $12M, eligible for up to $592M in Akebia deal - Stock Titan Mon, 01 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 175250 | 247102 | — | Stock Award(Grant) at price 1.41 per share. | BUTLER JOHN P | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 341305 | 474414 | — | Sale at price 1.39 per share. | BUTLER JOHN P | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 2 | 84829 | 117912 | — | Sale at price 1.39 per share. | GRUND NICHOLAS | Officer | — | 2026-02-02 00:00:00 | D |
| 3 | 34951 | 48582 | — | Sale at price 1.39 per share. | OSTROWSKI ERIK | Chairman of the Board | — | 2026-02-02 00:00:00 | D |
| 4 | 49524 | 68838 | — | Sale at price 1.39 per share. | MALABRE RICHARD C. | Officer | — | 2026-02-02 00:00:00 | D |
| 5 | 69772 | 96983 | — | Sale at price 1.39 per share. | RUCCI CAROLYN M | Officer | — | 2026-02-02 00:00:00 | D |
| 6 | 67658 | 94045 | — | Sale at price 1.39 per share. | BURKE STEVEN KEITH | Officer | — | 2026-02-02 00:00:00 | D |
| 7 | 743000 | — | — | Stock Award(Grant) at price 0.00 per share. | BUTLER JOHN P | Chief Executive Officer | — | 2026-01-30 00:00:00 | D |
| 8 | 204000 | — | — | Stock Award(Grant) at price 0.00 per share. | GRUND NICHOLAS | Officer | — | 2026-01-30 00:00:00 | D |
| 9 | 204000 | — | — | Stock Award(Grant) at price 0.00 per share. | OSTROWSKI ERIK | Chairman of the Board | — | 2026-01-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -12.82M | -7.56M | -24.00M | -226.53M |
| TotalUnusualItems | -905.00K | -705.00K | -16.84M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -905.00K | -705.00K | -16.84M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -69.41M | -51.92M | -94.23M | -282.02M |
| ReconciledDepreciation | 37.50M | 37.63M | 37.70M | 37.97M |
| ReconciledCostOfRevenue | 63.18M | 74.15M | 85.57M | 150.67M |
| EBITDA | -13.72M | -8.27M | -40.84M | -226.53M |
| EBIT | -51.23M | -45.89M | -78.54M | -264.50M |
| NetInterestIncome | -18.18M | -6.03M | -15.69M | -19.94M |
| InterestExpense | 18.18M | 6.03M | 15.69M | 19.94M |
| NormalizedIncome | -68.50M | -51.22M | -77.39M | -282.02M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -69.41M | -51.92M | -94.23M | -282.02M |
| TotalExpenses | 210.59M | 240.70M | 357.33M | 476.15M |
| TotalOperatingIncomeAsReported | -50.47M | -46.26M | -80.78M | -264.50M |
| DilutedAverageShares | 210.95M | 187.47M | 182.78M | 165.95M |
| BasicAverageShares | 210.95M | 187.47M | 182.78M | 165.95M |
| DilutedEPS | -0.33 | -0.28 | -0.51 | -1.70 |
| BasicEPS | -0.33 | -0.28 | -0.51 | -1.70 |
| DilutedNIAvailtoComStockholders | -69.41M | -51.92M | -94.23M | -282.02M |
| NetIncomeCommonStockholders | -69.41M | -51.92M | -94.23M | -282.02M |
| NetIncome | -69.41M | -51.92M | -94.23M | -282.02M |
| NetIncomeIncludingNoncontrollingInterests | -69.41M | -51.92M | -94.23M | -282.02M |
| NetIncomeContinuousOperations | -69.41M | -51.92M | -94.23M | -282.02M |
| TaxProvision | 0.00 | 0.00 | ||
| PretaxIncome | -69.41M | -51.92M | -94.23M | -282.02M |
| OtherIncomeExpense | -811.00K | 182.00K | -13.69M | 2.41M |
| OtherNonOperatingIncomeExpenses | 94.00K | 887.00K | 3.15M | 2.41M |
| SpecialIncomeCharges | -575.00K | -705.00K | -16.84M | 0.00 |
| OtherSpecialCharges | 517.00K | 524.00K | 906.00K | |
| RestructuringAndMergernAcquisition | 58.00K | 181.00K | 15.93M | 0.00 |
| GainOnSaleOfSecurity | -330.00K | |||
| NetNonOperatingInterestIncomeExpense | -18.18M | -6.03M | -15.69M | -19.94M |
| TotalOtherFinanceCost | 15.69M | 19.94M | ||
| InterestExpenseNonOperating | 18.18M | 6.03M | 15.69M | 19.94M |
| OperatingIncome | -50.41M | -46.08M | -64.85M | -264.50M |
| OperatingExpense | 147.42M | 166.55M | 271.76M | 325.48M |
| OtherOperatingExpenses | 3.22M | 3.24M | 3.17M | 3.49M |
| ResearchAndDevelopment | 37.65M | 63.08M | 129.99M | 147.85M |
| SellingGeneralAndAdministration | 106.55M | 100.23M | 138.60M | 174.14M |
| SellingAndMarketingExpense | 100.23M | 138.60M | 174.14M | |
| GeneralAndAdministrativeExpense | 141.87M | 177.65M | ||
| OtherGandA | 141.87M | 177.65M | ||
| GrossProfit | 97.00M | 120.47M | 206.92M | 60.98M |
| CostOfRevenue | 63.18M | 74.15M | 85.57M | 150.67M |
| TotalRevenue | 160.18M | 194.62M | 292.48M | 211.65M |
| OperatingRevenue | 160.18M | 194.62M | 292.48M | 211.65M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 224.85M | 194.58M | 184.14M | 177.00M |
| ShareIssued | 224.85M | 194.58M | 184.14M | 177.00M |
| TotalDebt | 47.64M | 48.12M | 99.78M | 136.05M |
| TangibleBookValue | -108.23M | -125.67M | -125.90M | -93.16M |
| InvestedCapital | -10.49M | 4.10M | 71.31M | 171.55M |
| WorkingCapital | 32.92M | 18.28M | 55.65M | 10.10M |
| NetTangibleAssets | -108.23M | -125.67M | -125.90M | -93.16M |
| CapitalLeaseObligations | 8.95M | 13.44M | 33.70M | 38.51M |
| CommonStockEquity | -49.19M | -30.58M | 5.23M | 74.01M |
| TotalCapitalization | -10.49M | -13.40M | 39.31M | 74.01M |
| TotalEquityGrossMinorityInterest | -49.19M | -30.58M | 5.23M | 74.01M |
| StockholdersEquity | -49.19M | -30.58M | 5.23M | 74.01M |
| GainsLossesNotAffectingRetainedEarnings | 6.00K | 6.00K | 6.00K | 6.00K |
| OtherEquityAdjustments | 6.00K | 6.00K | 6.00K | 6.00K |
| RetainedEarnings | -1.68B | -1.61B | -1.56B | -1.46B |
| AdditionalPaidInCapital | 1.63B | 1.58B | 1.56B | 1.54B |
| CapitalStock | 2.00K | 2.00K | 2.00K | 1.00K |
| CommonStock | 2.00K | 2.00K | 2.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 269.86M | 272.29M | 350.82M | 455.34M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 188.94M | 172.42M | 221.29M | 194.29M |
| OtherNonCurrentLiabilities | 103.51M | 62.90M | 73.20M | 137.29M |
| DerivativeProductLiabilities | 5.18M | 0.00 | 760.00K | 1.82M |
| NonCurrentDeferredLiabilities | 0.00 | 43.30M | 43.30M | 21.47M |
| NonCurrentDeferredRevenue | 0.00 | 43.30M | 43.30M | 21.47M |
| LongTermDebtAndCapitalLeaseObligation | 42.24M | 26.13M | 63.04M | 33.70M |
| LongTermCapitalLeaseObligation | 3.55M | 8.95M | 28.96M | 33.70M |
| LongTermDebt | 38.69M | 17.18M | 34.08M | |
| LongTermProvisions | 38.01M | 40.09M | 40.99M | |
| CurrentLiabilities | 80.91M | 99.87M | 129.54M | 261.05M |
| OtherCurrentLiabilities | 6.11M | 4.60M | 6.58M | |
| CurrentDeferredLiabilities | 0.00 | 3.74M | 20.91M | |
| CurrentDeferredRevenue | 0.00 | 3.74M | 20.91M | |
| CurrentDebtAndCapitalLeaseObligation | 5.40M | 21.99M | 36.74M | 102.34M |
| CurrentCapitalLeaseObligation | 5.40M | 4.49M | 4.74M | 4.80M |
| CurrentDebt | 17.50M | 32.00M | 97.54M | |
| OtherCurrentBorrowings | 17.50M | 32.00M | 97.54M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.19M | 8.22M | 11.89M | |
| CurrentProvisions | 21.02M | 28.36M | 34.06M | 31.18M |
| PayablesAndAccruedExpenses | 39.18M | 36.70M | 36.53M | 106.62M |
| CurrentAccruedExpenses | 24.00M | 22.07M | 18.51M | 73.03M |
| Payables | 15.18M | 14.63M | 18.02M | 33.59M |
| AccountsPayable | 15.18M | 14.63M | 18.02M | 33.59M |
| TotalAssets | 220.67M | 241.70M | 356.05M | 529.35M |
| TotalNonCurrentAssets | 106.84M | 123.55M | 170.87M | 258.20M |
| OtherNonCurrentAssets | 37.38M | 12.42M | 5.37M | 50.42M |
| GoodwillAndOtherIntangibleAssets | 59.04M | 95.09M | 131.13M | 167.17M |
| OtherIntangibleAssets | 36.04M | 72.08M | 108.13M | |
| Goodwill | 59.04M | 59.04M | 59.04M | 59.04M |
| NetPPE | 10.42M | 16.05M | 34.37M | 40.61M |
| AccumulatedDepreciation | -9.32M | -7.67M | ||
| GrossPPE | 10.42M | 16.05M | 34.37M | 48.27M |
| Leases | 8.69M | 8.57M | ||
| OtherProperties | 10.42M | 16.05M | 34.37M | 36.60M |
| MachineryFurnitureEquipment | 3.10M | 3.10M | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 113.83M | 118.15M | 185.18M | 271.15M |
| OtherCurrentAssets | 7.32M | 5.75M | 32.86M | 33.14M |
| PrepaidAssets | 4.03M | 14.49M | 33.14M | |
| Inventory | 16.24M | 15.69M | 21.57M | 36.63M |
| FinishedGoods | 4.21M | 11.39M | 13.68M | |
| WorkInProcess | 12.03M | 4.30M | 7.89M | |
| Receivables | 34.37M | 39.29M | 40.28M | 51.58M |
| AccountsReceivable | 34.37M | 39.29M | 40.28M | 51.58M |
| AllowanceForDoubtfulAccountsReceivable | -1.21M | -1.03M | ||
| GrossAccountsReceivable | 35.58M | 40.32M | ||
| CashCashEquivalentsAndShortTermInvestments | 51.87M | 42.92M | 90.47M | 149.80M |
| OtherShortTermInvestments | 0.00 | |||
| CashAndCashEquivalents | 51.87M | 42.92M | 90.47M | 149.80M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -40.69M | -23.38M | -73.27M | -253.02M |
| RepurchaseOfCapitalStock | -1.27M | 0.00 | 0.00 | |
| RepaymentOfDebt | -37.10M | -32.00M | -33.00M | 0.00 |
| IssuanceOfDebt | 45.00M | 0.00 | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 42.65M | 6.79M | 7.53M | 88.95M |
| CapitalExpenditure | -33.00K | -114.00K | -59.00K | |
| InterestPaidSupplementalData | 5.04M | 6.06M | 6.75M | 9.63M |
| EndCashPosition | 53.55M | 44.58M | 93.17M | 151.84M |
| BeginningCashPosition | 44.58M | 93.17M | 151.84M | 231.13M |
| ChangesInCash | 8.97M | -48.59M | -58.67M | -79.29M |
| FinancingCashFlow | 49.66M | -25.21M | 14.60M | 133.73M |
| CashFlowFromContinuingFinancingActivities | 49.66M | -25.21M | 14.60M | 133.73M |
| NetOtherFinancingCharges | 40.00M | 44.78M | ||
| ProceedsFromStockOptionExercised | 385.00K | 1.00K | 67.00K | 0.00 |
| NetCommonStockIssuance | 41.38M | 6.79M | 7.53M | 88.95M |
| CommonStockPayments | -1.27M | 0.00 | 0.00 | |
| CommonStockIssuance | 42.65M | 6.79M | 7.53M | 88.95M |
| NetIssuancePaymentsOfDebt | 7.90M | -32.00M | -33.00M | 0.00 |
| NetLongTermDebtIssuance | 7.90M | -32.00M | -33.00M | 0.00 |
| LongTermDebtPayments | -37.10M | -32.00M | -33.00M | 0.00 |
| LongTermDebtIssuance | 45.00M | 0.00 | 0.00 | 0.00 |
| InvestingCashFlow | -33.00K | 0.00 | -114.00K | 39.94M |
| CashFlowFromContinuingInvestingActivities | -33.00K | 0.00 | -114.00K | 39.94M |
| NetInvestmentPurchaseAndSale | 0.00 | 40.00M | ||
| SaleOfInvestment | 0.00 | 40.00M | ||
| PurchaseOfInvestment | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -33.00K | 0.00 | -114.00K | -59.00K |
| PurchaseOfPPE | -33.00K | 0.00 | -114.00K | -59.00K |
| OperatingCashFlow | -40.66M | -23.38M | -73.15M | -252.97M |
| CashFlowFromContinuingOperatingActivities | -40.66M | -23.38M | -73.15M | -252.97M |
| ChangeInWorkingCapital | -39.68M | -20.73M | -1.44M | -105.61M |
| ChangeInOtherWorkingCapital | -3.74M | 4.65M | 1.82M | |
| ChangeInOtherCurrentLiabilities | -10.70M | -10.65M | 4.59M | 2.23M |
| ChangeInOtherCurrentAssets | 622.00K | -1.36M | -5.62M | -8.21M |
| ChangeInPayablesAndAccruedExpense | -14.14M | -15.27M | -36.50M | -33.81M |
| ChangeInAccruedExpense | -12.78M | -10.02M | -38.01M | -22.08M |
| ChangeInPayable | -1.36M | -5.24M | 1.50M | -11.73M |
| ChangeInAccountPayable | -1.36M | -5.24M | 1.50M | -11.73M |
| ChangeInPrepaidAssets | 8.89M | 11.84M | 1.06M | -18.66M |
| ChangeInInventory | -28.40M | -2.54M | 19.09M | -24.95M |
| ChangeInReceivables | 4.05M | 994.00K | 11.30M | -24.03M |
| ChangesInAccountReceivables | 4.05M | 994.00K | 11.30M | -24.03M |
| OtherNonCashItems | 17.44M | 1.50M | -62.62M | 37.96M |
| StockBasedCompensation | 7.78M | 9.32M | 17.85M | 22.73M |
| ProvisionandWriteOffofAssets | 4.21M | 1.58M | 30.24M | |
| AssetImpairmentCharge | 876.00K | 0.00 | 30.24M | 36.62M |
| AmortizationOfSecurities | 0.00 | -15.00K | ||
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 37.50M | 37.63M | 37.70M | 37.97M |
| DepreciationAndAmortization | 37.50M | 37.63M | 37.70M | 37.97M |
| AmortizationCashFlow | 36.04M | 36.04M | 36.04M | 36.04M |
| AmortizationOfIntangibles | 36.04M | 36.04M | 36.04M | 36.04M |
| Depreciation | 1.46M | 1.58M | 1.65M | 1.93M |
| OperatingGainsLosses | 624.00K | -760.00K | -654.00K | -600.00K |
| GainLossOnInvestmentSecurities | 330.00K | -760.00K | -1.06M | -600.00K |
| NetIncomeFromContinuingOperations | -69.41M | -51.92M | -94.23M | -282.02M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AKBA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|